We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?
Read MoreHide Full Article
Canopy Growth Corporation (CGC - Free Report) is scheduled to report first-quarter fiscal 2022 results on Aug 6, before the opening bell.
In the fourth quarter of fiscal 2021, the company reported a loss of 66 cents. The Zacks Consensus Estimate was pegged at a loss of 18 cents.
The company missed estimates in two of the trailing four quarters and surpassed the same in the other two, the average negative surprise being 108.8%.
Let's take a look at how things are shaping up prior to this announcement.
Factors at Play
Canopy Growth, which is well positioned in the growing Canadian recreational cannabis market, has lately been witnessing strength in its business channels amid the post-pandemic recovery. During the fourth-quarter earnings call, the company noted that despite a challenging industry backdrop, Canada’s recreational business outperformed many of the country’s LPs. This trend is likely to have continued during the first-quarter fiscal 2022 as well, considering the improved market scenario.
The company’s U.S. cannabidiol (CBD) business is gaining momentum over the past few months on the back of its highly-successful Martha Stewart CBD product launches. In April 2021, Canopy Growth launched Quatreau CBD beverages in the United States and became the first U.S. CBD beverage brand to sign with a major beverage distributor, Southern Glazer’s Wine & Spirit. During the June 2021 update, the company noted that its February-launched Canopy's first gummy in Canada — Twd. Strawberry — has been witnessing strong demand. On continued strong rollout and developments, this trend has likely continued through the fiscal first quarter, adding to its top line.
Over the past few months, BioSteel Sports Nutrition Inc., Canopy Growth’s acquired business, has been witnessing continued momentum driven by Amazon U.K. and U.S. expansion. Further, BioSteel has unveiled a long-term brand ambassador partnership with All-Star basketball player, Luka Doncic of the Dallas Maverick and has secured multi-year partnership with the U.S. Soccer Federation. These developments are likely to have considerably driven fiscal first-quarter revenues.
During the fourth-quarter earnings call, the company confirmed that its acquired business Storz & Bickel vaporizer continues to grow on expanded distribution in the United States, broader product portfolio and increased consumer pool. This trend is likely to have continued in the first quarter as well, adding to the top line.
The company’s This Works brand of products is expected to have registered solid U.S. retail growth in the fiscal first quarter on the back of strength in sales of Amazon, thisworks.com, ULTA, and Nordstrom.
The company’s share in the ready-to-drink category in Ontario has also been robust over the past few months. In June 2021, the company acquired Supreme Cannabis — one of the top 10 licensed producers in Canada with a leading premium brand portfolio. The acquisition adds a low-cost, scalable cultivation facility at Kincardine, Ontario. In April, the company launched Vert — the company’s first Quebec-exclusive brand. With the launch, it brings a new offering of local cannabis flower to SQDC shelves. These developments are expected to have contributed significantly during the fiscal first quarter, adding to the top line.
The Estimate Picture
The Zacks Consensus Estimate for total fiscal first-quarter revenues of $127.8 million suggests growth of 48.7% from the prior-year quarter’s reported figure.
The consensus mark for loss stands at 19 cents per share for the fiscal first quarter. It had reported loss of 20 cents per share in the year-ago quarter.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for Canopy Growth this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, this is not the case here as you can see:
Earnings ESP: Canopy Growth has an Earnings ESP of +30.85%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are a few medical stocks worth considering as these also have the right combination of elements to beat on earnings this reporting cycle.
Illumina, Inc. (ILMN - Free Report) has an Earnings ESP of +2.36% and a Zacks Rank of 2, at present. The stock is slated to release second-quarter 2021 results on Aug 5.
Henry Schein, Inc. (HSIC - Free Report) has an Earnings ESP of +0.45% and is a Zacks #2 Ranked stock. The company is slated to release its second-quarter 2021 results on Aug 3.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?
Canopy Growth Corporation (CGC - Free Report) is scheduled to report first-quarter fiscal 2022 results on Aug 6, before the opening bell.
In the fourth quarter of fiscal 2021, the company reported a loss of 66 cents. The Zacks Consensus Estimate was pegged at a loss of 18 cents.
The company missed estimates in two of the trailing four quarters and surpassed the same in the other two, the average negative surprise being 108.8%.
Let's take a look at how things are shaping up prior to this announcement.
Factors at Play
Canopy Growth, which is well positioned in the growing Canadian recreational cannabis market, has lately been witnessing strength in its business channels amid the post-pandemic recovery. During the fourth-quarter earnings call, the company noted that despite a challenging industry backdrop, Canada’s recreational business outperformed many of the country’s LPs. This trend is likely to have continued during the first-quarter fiscal 2022 as well, considering the improved market scenario.
The company’s U.S. cannabidiol (CBD) business is gaining momentum over the past few months on the back of its highly-successful Martha Stewart CBD product launches. In April 2021, Canopy Growth launched Quatreau CBD beverages in the United States and became the first U.S. CBD beverage brand to sign with a major beverage distributor, Southern Glazer’s Wine & Spirit. During the June 2021 update, the company noted that its February-launched Canopy's first gummy in Canada — Twd. Strawberry — has been witnessing strong demand. On continued strong rollout and developments, this trend has likely continued through the fiscal first quarter, adding to its top line.
Canopy Growth Corporation Price and EPS Surprise
Canopy Growth Corporation price-eps-surprise | Canopy Growth Corporation Quote
Over the past few months, BioSteel Sports Nutrition Inc., Canopy Growth’s acquired business, has been witnessing continued momentum driven by Amazon U.K. and U.S. expansion. Further, BioSteel has unveiled a long-term brand ambassador partnership with All-Star basketball player, Luka Doncic of the Dallas Maverick and has secured multi-year partnership with the U.S. Soccer Federation. These developments are likely to have considerably driven fiscal first-quarter revenues.
During the fourth-quarter earnings call, the company confirmed that its acquired business Storz & Bickel vaporizer continues to grow on expanded distribution in the United States, broader product portfolio and increased consumer pool. This trend is likely to have continued in the first quarter as well, adding to the top line.
The company’s This Works brand of products is expected to have registered solid U.S. retail growth in the fiscal first quarter on the back of strength in sales of Amazon, thisworks.com, ULTA, and Nordstrom.
The company’s share in the ready-to-drink category in Ontario has also been robust over the past few months. In June 2021, the company acquired Supreme Cannabis — one of the top 10 licensed producers in Canada with a leading premium brand portfolio. The acquisition adds a low-cost, scalable cultivation facility at Kincardine, Ontario. In April, the company launched Vert — the company’s first Quebec-exclusive brand. With the launch, it brings a new offering of local cannabis flower to SQDC shelves. These developments are expected to have contributed significantly during the fiscal first quarter, adding to the top line.
The Estimate Picture
The Zacks Consensus Estimate for total fiscal first-quarter revenues of $127.8 million suggests growth of 48.7% from the prior-year quarter’s reported figure.
The consensus mark for loss stands at 19 cents per share for the fiscal first quarter. It had reported loss of 20 cents per share in the year-ago quarter.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for Canopy Growth this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, this is not the case here as you can see:
Earnings ESP: Canopy Growth has an Earnings ESP of +30.85%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are a few medical stocks worth considering as these also have the right combination of elements to beat on earnings this reporting cycle.
Envista Holdings Corporation (NVST - Free Report) has an Earnings ESP of +1.94% and a Zacks Rank #2, currently. The stock is slated to release second-quarter 2021 results on Aug 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Illumina, Inc. (ILMN - Free Report) has an Earnings ESP of +2.36% and a Zacks Rank of 2, at present. The stock is slated to release second-quarter 2021 results on Aug 5.
Henry Schein, Inc. (HSIC - Free Report) has an Earnings ESP of +0.45% and is a Zacks #2 Ranked stock. The company is slated to release its second-quarter 2021 results on Aug 3.